About
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of...
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

Executive Management :

Mr. Sven Rohmann ( Chief Executive Officer )
Mr. Peter Hein ( Chief Financial Officer )
Dr. Alex Karlsson-Parra ( Chief Scientific Officer )
Dr. Sharon Longhurst ( Head of CMC )
Mrs. Margareth Jorvid ( Head of Regulation and QA )
Mr. Sijme Zeilemaker ( Chief Operating Officer )
Mr. Peter Suenaert ( Chief Medical Officer )

Board of Directors :

Mr. Michael Oredsson ( Chairman )
Dr. Charlotte Edenius ( Director )
Dr. Steven Glazer ( Director )
Mrs. Christine Lind ( Board Member )
Dr. Helén Tuvesson ( Board Member )
Mr. Sven Andreasson ( Board Member )